Sunday, November 26 | 9:20 a.m.-9:30 a.m. | S1-SSNMMI01-3 | Room E350
Gallium-68 (Ga-68) RM2-PET imaging should be considered in patients with biochemical recurrent (BCR) prostate cancer to aid in disease detection and management decisions, according to a study to be presented in this session.
National Comprehensive Cancer Network guidelines include prostate-specific membrane antigen (PSMA) PET for the detection of BCR, yet up to 10% of cases do not express PSMA, noted presenter Heying Duan, MD, a nuclear medicine research scientist at Stanford University.
Duan and colleagues developed a tracer called Ga-68 RM2, which targets overexpressed gastrin-releasing peptide receptors (GRPRs) in prostate cancer, with evidence to be presented on its use from a phase II/III trial in 100 patients. The primary endpoint of the study was met, with Ga-68 RM2-PET/MRI showing significantly higher detection rates than MRI alone (143 vs. 96 lesions), according to the results.
“Thus, GRPR-targeted PET imaging is a valuable tool in the imaging armamentarium of prostate cancer at biochemical recurrence,” noted Duan, who received a Trainee Research Prize for fellows for the work.
Check out this scientific session on prostate cancer imaging to learn all of the details.